Lipocine Inc. · NASDAQ:LPCN

Lipocine — Investor Presentation (March 2026)

5 slides from Lipocine's investor presentation, March 2026

  1. Slide 1: LPCN 2101 Treatment of Epilepsy

    LPCN 2101 Treatment of Epilepsy

  2. Slide 2: Drug-Resistant Epilepsy (DRE)

    Drug-Resistant Epilepsy (DRE) A significant clinical challenge in epilepsy care with high social and occupational limitations1 Prevalence Affects 30-40% of epilepsy patients in the U.S. 2 Clinical Increased risk of injury, hospitalization, mortality, and mental DRE is defined by ILAE as Impact healt

  3. Slide 3: Unmet Needs in DRE

    Unmet Needs in DRE Seizure freedom without adverse effects, while improving the patient's quality of life Limitations of Current Options • 30–40% of patients still do not achieve freedom from seizures, despite being on multiple medications • Many patients with DRE go through multiple ASMs with limit

  4. Slide 4: LPCN 2101 – NAS for Epilepsy Treatment

    LPCN 2101 – NAS for Epilepsy Treatment Positive Allosteric Modulator (PAM) of the GABAA receptor Product Candidate Anti-Seizure Activity in First Oral Enablement Differentiation Preclinical Models Phase 1 Results 40 • Novel MOA specifically • Effective in most of the tonic Mean Plasma Concentration

  5. Slide 5: LPCN 2101 Development Status

    LPCN 2101 Development Status Phase 2 ready Preclinical PK Preclinical Toxicity Phase 1 Studies Next Steps ✓ First oral enablement ✓ Chronic ✓ IND cleared o Initiate P2 study demonstrated administration was safe and well ✓ Confirmed oral ✓ Achieved ~10x of tolerated enablement estimated highest targe

Lipocine — Investor Presentation (March 2026) on 6ix